Xuehui He

Radboud University Medical Centre

Dr. Xuehui He received her Ph.D. at Tübingen University, Germany. After graduation, she moved to Radboud University Medical Center, Netherlands, to investigate the regulation of the human immune system in relation to immune-mediated-diseases. Her research interests include the maintenance of human Treg stability and identity, developing novel small-molecule-inhibitors, and immune profiling of patients with distinct autoimmune diseases including psoriasis, psoriatic arthritis, and type 1 diabetes as well as cancer patients undergoing treatment with checkpoint inhibitors. With the advent of high-throughput techniques and the availability of multi-omics data generated from a large set of samples, Dr. Xuehui He is also specialized in applying various tools and methods for data integration, analysis and interpretation. She believes that combining multi-omics data to highlight the interrelationships of the involved biomolecules and their functions is crucial to fully understand human health and diseases.

Xuehui He

2books edited

1chapters authored

Latest work with IntechOpen by Xuehui He

In healthy humans, effector immune cells are activated by the presence of pathogens. Various signaling pathways coordinate the growth and proliferation of the immune cells to fight the invading pathogen and keep the host healthy. A portion of white blood cells known as regulatory T cells (Treg) help to control the rapid proliferation of effector immune cells including effector T cells as well as antigen-presenting cells to make sure the inflammation is kept in check. When Treg cells are depleted or undergo loss of suppressive functionality, hyperinflammatory disease results. However, Treg depletion can also provoke and enhance tumor immunity. Therefore, targeting Treg cells is a promising approach for both autoimmune disease and cancer immunotherapy. To attenuate or enhance Treg-mediated immune suppression, it is necessary to find a specific molecular marker that can selectively and reliably differentiate between Treg and effector T cells. Further elucidation of the cellular and molecular processes underlying the development and function of regulatory immune cells will help to establish new strategies for the treatment and prevention of immune-mediated disease.

Go to the book